Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
Roger BedimoInfectious Disease section, VA North Texas Health Care System, TX, USAAbstract: HIV-infected patients on highly active antiretroviral therapy (HAART) develop a complex of body composition changes known, including peripheral fat loss (lipoatrophy) and central fat accumulation (lipohypertr...
Guardado en:
Autor principal: | Bedimo R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/077f68c999454baf9a932f0acba231b4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lipodystrophy in HIV patients: its challenges and management approaches
por: Singhania R, et al.
Publicado: (2011) -
New and emerging agents in the management of lipodystrophy in HIV-infected patients
por: Eric Bonnet
Publicado: (2010) -
Role of darunavir in the management of HIV infection
por: R Monica Lascar, et al.
Publicado: (2009) -
Role of raltegravir in the management of HIV-1 infection
por: Okeke NL, et al.
Publicado: (2011) -
Profile of darunavir in the management of treatment-experienced HIV patients
por: Cameron Wolfe, et al.
Publicado: (2009)